ONCOLYTICS BIOTECH INC | CIK:0001129928 | 3

  • Filed: 3/19/2018
  • Entity registrant name: ONCOLYTICS BIOTECH INC (CIK: 0001129928)
  • Generator: Workiva (WebFilings)
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/0001129928-18-000028-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/oncyf-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001129928
  • Open this page in separate window: Click
  • ifrs-full:DisclosureOfRelatedPartyExplanatory

    Related Party Transactions

    Compensation of Key Management Personnel
    Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain officers of the Company.

    2017
    $
    2016
    $
    2015
    $
    Short-term employee compensation and benefits
    2,596,082

    2,753,553

    2,941,342

    Termination benefits
    779,666

    1,330,828


    Share-based payments
    459,298

    372,008

    353,419


    3,835,046

    4,456,389

    3,294,761



    Assumption Agreement
    In November 2017, with the signing of a regional licensing agreement with upfront license fees (see Note 10), the Company triggered a liability of US$178,125 to an officer as detailed in the Assumption Agreement (see Note 12). As at December 31, 2017, US$178,125 was included in accounts payable and accrued liabilities. US$35,625 was paid in January 2018 and the balance will be paid after receipt of the contract receivable from Adlai.